Germany · Delayed Price · Currency is EUR Corvus Pharmaceuticals Statistics
Total Valuation
FRA:C17 has a market cap or net worth of EUR 546.69 million. The enterprise value is 491.06 million.
| Market Cap | 546.69M |
| Enterprise Value | 491.06M |
Important Dates
The next estimated earnings date is Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 74.68M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +34.14% |
| Shares Change (QoQ) | +6.51% |
| Owned by Insiders (%) | 3.95% |
| Owned by Institutions (%) | 38.85% |
| Float | 58.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 8.94 |
| P/TBV Ratio | 8.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -38.22 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.88 |
Financial Position
The company has a current ratio of 8.29, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.29 |
| Quick Ratio | 8.18 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.82% and return on invested capital (ROIC) is -56.78%.
| Return on Equity (ROE) | -35.82% |
| Return on Assets (ROA) | -34.87% |
| Return on Invested Capital (ROIC) | -56.78% |
| Return on Capital Employed (ROCE) | -53.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -414,465 |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.66% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.66% |
| 50-Day Moving Average | 6.45 |
| 200-Day Moving Average | 4.33 |
| Relative Strength Index (RSI) | 65.24 |
| Average Volume (20 Days) | 210 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.12M |
| Pretax Income | -12.85M |
| Net Income | -12.85M |
| EBITDA | -33.04M |
| EBIT | -33.12M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
The company has 55.99 million in cash and 861,675 in debt, giving a net cash position of 55.13 million.
| Cash & Cash Equivalents | 55.99M |
| Total Debt | 861,675 |
| Net Cash | 55.13M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 61.17M |
| Book Value Per Share | 0.82 |
| Working Capital | 50.17M |
Cash Flow
In the last 12 months, operating cash flow was -27.33 million and capital expenditures -126,993, giving a free cash flow of -27.46 million.
| Operating Cash Flow | -27.33M |
| Capital Expenditures | -126,993 |
| Free Cash Flow | -27.46M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:C17 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.14% |
| Shareholder Yield | -34.14% |
| Earnings Yield | -2.35% |
| FCF Yield | -5.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |